Opinion
Video
The panel highlights the quality of life and emotional challenges faced by patients diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Jonathon Abbas, MD; Vivian Tambe Tar, PharmD, MBA; Elias Jabbour, MD; and James McCloskey, MD.
The discussants focus on the impact of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and its treatment relating to patients' quality of life (QOL) and emotional well-being. Abbas noted the wide variation in patient age, from teenagers to octogenarians, each requiring personalized supportive care. The typically months-long treatment regimens with frequent clinic visits can be burdensome, especially for younger patients who may be building careers or families. Haumschild emphasized considering QOL goals, such as the ability to work and maintain mental health and relationships with loved ones. Monitoring QOL and adjusting care accordingly should be part of the treatment approach. The toxicity burden and its impact also require special attention in older patients with comorbidities. Overall, supporting patients with Ph+ ALL holistically emerges as a key priority.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.